Big Pharma Is Cheating Americans Out of Publicly Funded Drugs / by Helen Santoro

Eliquis is one of ten prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Farxiga, Xarelto, Entresto, Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. (Scott Olson / Getty Images)

A new report reveals that Americans funded the development of all ten drugs up for price negotiations with Medicare, but Big Pharma still wants to keep prices for those publicly funded drugs sky high.

Reposted from Jacobin


As the government begins its first-ever price negotiations for a handful of medicines under Medicare, the pharmaceutical industry has launched an all-out legal and PR assault on this meager attempt to control out-of-control drug prices for the country’s most vulnerable. Big Pharma reasons that the government has no place setting prices for the drugs developed by private companies.

But the government, and by extension taxpayers, heavily subsidizes the development of drugs in this country. Now a bombshell new report reveals that Americans funded the development of all ten drugs up for price negotiations, shelling out a total of $11.7 billion on their research. In 2022 alone, Big Pharma made $70 billion selling those same drugs — and now it wants to keep their prices sky high.

According to the new study out of the Center for Integration of Science and Industry at Bentley University, which has not yet been published, the ten selected prescription drugs received anywhere from $227 million to $6.5 billion in funding from the government’s National Institutes of Health (NIH) for crucial, foundational research.

“When the average taxpayer is paying for the drug, it’s not just what’s being paid at the pharmacy,” said Fred Ledley, professor of natural and applied sciences at Bentley and senior author on the study.

These drugs, which are covered by Medicare’s prescription drug benefit plan, are taken by 7.7 million enrollees, most of them elderly, to treat conditions including blood clots, heart failure, diabetes, autoimmune conditions, and chronic kidney disease. In 2022, Medicare patients spent $3.4 billion out of pocket on these medications, a number that increased by 116 percent over a four-year span.

From 2018 to 2022, out-of-pocket costs for Medicare enrollees climbed for nine of the ten drugs. The average annual out-of-pocket cost for Stelara, an injectable drug that treats autoimmune conditions, rose the most from $709 per enrollee to $2,058. For non-Medicare US patients, Stelara can be considerably more expensive, especially since drugmakers charge far higher prices in this country than they do elsewhere. A 2019 report found that the regular price for Stelara was $16,600 per dose in the United States, compared to $2,900 per dose in the United Kingdom.

According to the new report from Bentley University, the Johnson & Johnson subsidiary that developed Stelara received $6.5 billion in taxpayer funding for it — by far the most of any of the medicines up for price negotiations.

Total Medicare spending to pay for enrollees’ use of these vital drugs more than doubled from about $20 billion in 2018 to $50.5 billion in 2023. Paying for these particular drugs accounted for roughly 20 percent of all Medicare spending on prescription drugs between summer 2022 and spring 2023.

Pharmaceutical Research and Manufacturers of America (PhRMA), the pharmaceutical industry’s main lobbying group, said it could not comment on the specifics of a study it has not reviewed.

Sarah Ryan, PhRMA’s senior manager of public affairs, added in an email to us that “while the NIH plays a crucial role in fostering basic research, private industry contributions, both financial and technical, are instrumental in turning discoveries into fully developed therapies for patients. There is a rich body of research documenting the nature of these complementary roles, which overwhelmingly demonstrates that the private sector invests significantly more and takes on far greater risk in drug development than the government.”

After finalizing negotiations with the drug manufacturers, the Centers for Medicare and Medicaid Services, which oversees all federal health programs, will publish the agreed-upon drug prices by September 1, 2024, and the new prices will go into effect starting January 1, 2026.

Essential Basic Research

The rising cost of prescription drugs is a critical issue in American health care. From 2008 to 2021, the launch prices of new drugs increased by 20 percent per year, forcing eighteen million Americans to skip essential dosages, according to a 2021 Gallup survey of adults nationwide.

High prices are particularly harmful for lower-income households. Of survey respondents earning less than $48,000 per year, 18 percent reported they or someone in their home had skipped a dose to save money. More than five million Medicare beneficiaries struggle to afford their prescriptions, particularly those who do not receive a low-income subsidy that lowers out-of-pocket spending. Additionally, black and Latino enrollees report affordability problems at 1.5 to 2 times the rate of their white counterparts.

In prior years, the federal government didn’t have the power to haggle with pharmaceutical manufacturers over Medicare drug prices. But that changed thanks to the Inflation Reduction Act, signed by President Joe Biden in 2022, which allowed Medicare drug-price negotiations and other pharmaceutical cost-cutting measures. The legislation has already capped out-of-pocket spending for insulin at $35 per month for Medicare beneficiaries. As Medicare expands its price negotiations to cover eighty drugs by 2030, the act is estimated to save the government $237 billion by 2031.

In the wake of the government announcing its starting-bid prices for the first ten drugs up for negotiation, an analysis by the public-policy advocacy group Center for American Progress concluded the process could cut the drugs’ prices by as much as $6,500 a month.

As pharmaceutical interests launched their offensive against these price negotiations, a report published by the US Department of Health and Human Services last December found that of the ten drugs selected, seven received at least one form of federal support as part of their research and development.

But the new report from the Center for Integration of Science and Industry goes further, finding that all ten drugs received funding from the federal government. This is because while the government report only focused on money going toward applied research, meaning efforts to develop a particular drug, Ledley and his colleagues also looked at funding for basic science — the key, foundational research that identifies a biological target, like a protein or gene, that may be linked to a disease and is the first step in drug development.

“When most people look at what the government is paying for, they’re only looking at the applied science,” said Ledley.

Basic science is crucial in the development of transformative medicine, according to a 2018 study. Researchers examined twenty-eight significant medicines approved by the US Food and Drug Administration between 1985 and 2009 and found that 80 percent of them could be traced back to basic research that sought to understand a biological process or disease.

According to the Bentley University study, NIH funding on the ten Medicare medications up for price negotiations ranged from $228 million to $6.5 billion per drug. Here’s the breakdown:

  • Stelara, developed by Johnson & Johnson Innovative Medicine: $6.5 billion
  • Enbrel, developed by Immunex Corporation: $2.6 billion
  • Entresto, developed by Novartis: $901 million
  • Eliquis, developed by Bristol Myers Squibb and Pfizer: $791 million
  • Xarelto, developed by Bayer and Johnson & Johnson Innovative Medicine: $764 million
  • Imbruvica, developed by Johnson & Johnson Innovative Medicine and Pharmacyclics: $566 million
  • Farxiga, developed by AstraZeneca and Bristol Myers Squibb: $437 million
  • Jardiance, developed by Boehringer Ingelheim and Eli Lilly and Company: $434 million
  • Januvia, developed by Merck: $228 million

The specifics of government funding going toward foundational research for the final drug on the list — Novolog, which treats type 1 and type 2 diabetes — was not available because basic research on insulin occurred decades ago. The NIH did report spending $4.5 million on applied research for Novolog’s development.

While most of the government subsidies went to basic science behind these drugs, the NIH also spent more than $250 million on applied research for these medicines, amounting to about half of the total cost of bringing the drugs to market.

This public funding saved the drug industry billions in research and development costs. Now those drugs are making pharmaceutical companies billions. In 2022 alone, the medicines netted their manufacturers more than $70 billion in total revenue, according to our analysis. And some of these drugs have been on the market for twenty-five years.

“What makes the greed of the pharmaceutical industry so reprehensible is the fact that the American people are paying twice for some of the most expensive prescription drugs on the market: first through their taxes and a second time at the pharmacy counter,” Vermont senator Bernie Sanders told the US Senate Committee on Health, Education, Labor and Pensions last year.

Ledley doesn’t agree with the “paying twice” idea, since he and colleagues estimate the pharmaceutical industry is covering the majority of costs during the applied research and development stage. However, when it comes to drug pricing, “we think you have to include this public funding for developing the drug in your equation,” Ledley said.


Helen Santoro is a journalist based in Colorado.

Bidenomics Puts Business, Not Workers, First / by Doug Henwood

US president Joe Biden speaks about Bidenomics on November 29, 2023, in Pueblo, Colorado. (Michael Ciaglo / Getty Images)

Reposted from Jacobin


The Biden economy’s defenders claim it is delivering big gains to workers. But people are still feeling pain in their wallets and the rich are the ones benefiting the most.

Before the war in Gaza — before Joe Biden sank his reputation by enabling Israeli brutality — there was a debate about something called “Bidenomics.” Despite everything that’s upstaged it, it’s still worth a look.

Bidenomics never got much love. Interest peaked in July, according to Google Trends, and is down three-quarters since. It probably would be hard to find someone who could define it. For the Right, it’s practically Bolshevism. The president himself defines it as “building the economy from the middle out and bottom up — not the top down.” It rests, as things so often do, on three pillars: “First, making smart investments in America. Second, educating and empowering American workers to grow the middle class. And third, promoting competition to lower costs and help small businesses.”

How’s all that stand up to reality?

The Biden Economy

By the conventional indicators, especially measures of the labor market, the economy is strong, though perhaps a little past its peak. Reported evaluations are far less sunny than the official stats, however. Most people tell pollsters the economy stinks.

After extraordinary rates of growth in 2021 and 2022 as the economy recovered from the COVID shock, job growth is now slightly below its long-term average. The unemployment rate in October was 3.9 percent, very low by historical standards, though up 0.4 from April’s trough (which was the lowest rate since 1969). That’s the official rate, aka U-3, which has a fairly restrictive definition of unemployment. By the broader measure, U-6, which captures more people at the margins of the labor force, it was 7.2 percent. That’s up from December’s 2022 low of 6.5 percent, which was the lowest in that measure’s history.

Workers look strong in the labor market — the official count of unfilled job openings, a measure of employer frustration, though off its highs of spring 2022, is still high by historical standards, and similar could be said of the quit rate, a measure of worker confidence. Here too it looks like the worker’s labor market power has peaked but isn’t collapsing.

Add to this big union victories, from riveters to writers, and the US working class looks to be in its best shape in decades — which isn’t saying much given the standards of our history, but still, it’s better than nothing. Strike activity, which was more discursive than actual over the last couple of years, is finally showing up in the stats — though it’s got lots of ground to recover.

Tight labor markets have pushed up wages for the low paid, resulting in some decline in inequality, though just how much depends on the source. At the upbeat end, David Autor, Arindrajit Dube, and Annie McGrew find, to use the economic jargon, “compression” in the ratio of wages at the ninetieth percentile (those paid better than 90 percent of the population) to the tenth percentile (those with only 10 percent of the workforce paid less) since 2020. The worker shortage — “nobody wants to work anymore” — forced employers to boost wages among the lower paid faster than inflation, while the highest paid, many of them working remotely from their rural perches, had to cope with real wage declines. For the full period, January 2020–May 2023, Autor & Co. found the bottom 60 percent saw real wage increases — though if you start the clock in May 2021, only the bottom 40 percent did.

It may be that focusing on the very top and bottom — ninety and ten — gives a misleading impression of what’s going on with the masses. Other data sources paint a much less satisfying picture than Autor and his coauthors.

According to the Federal Reserve Bank of Atlanta, workers in the bottom half of the pay distribution saw nineteen consecutive months of yearly real wage declines in 2021 and 2022, and workers in the top half, twenty-three. According to another set of Atlanta Fed numbers, which adjust for changes in workforce composition — low-wage workers exited in large numbers in 2020, artificially boosting the average wage, and their return artificially depressed it in 2021 — average real hourly wages have fallen an average of 0.4 percent a year under Biden; under Trump, they rose 1.4 percent a year (which was three times Obama’s rate, by the way).

Another measure, the Federal Reserve Bank of New York’s estimates by demographic, show real weekly wages down 5.1 percent in the Biden years. Traditionally worse-off demographics are doing generally better than the more historically fortunate: younger doing better than older, those without college degrees doing better than those with, black and Latino doing better than white. But in most cases, those doing better are generally less negative than those doing worse. Real wages have turned positive in recent months as inflation has declined, but there’s lots to make up for.

Rising Prices, Declining Approval

Despite the easing of inflation — it was running at almost 8 percent a year in October 2022, and it was just over 3 percent this October — there’s been little change in the reported strain on household finances. The share of the population telling the Census Bureau’s Household Pulse Survey they were finding it very or somewhat difficult to pay their bills was 26 percent in April 2021, as the COVID relief money was flowing. That began rising, breaking 30 percent at the year’s end, and 40 percent in July 2022, where it’s stayed. It was 41 percent — 94 million adults — in October 2023.

The share reporting stress from price increases has fallen modestly, from 65 percent in October 2022 to 61 percent in June 2023. It’s stayed there since. Price stress most affects those on low incomes, of course — around 80 percent of those under $50,000 felt it. But almost half of those earning between $100,000 and $150,000 report price stress. The share of the population saying that they could get all the food they wanted was 72 percent before the pandemic; it’s now 54 percent.

Broader evaluations of the economy are no better. The University of Michigan’s monthly consumer sentiment survey, which goes back to 1952, has people rating the current economy below the average recorded in recessions, lower than 95 percent of the months since its inception.

According to a Financial Times–Michigan Ross Business School poll, people view the economy as miserable and Biden of little help. Just 43 percent of respondents report themselves as “thriving,” with the rest, 57 percent, “surviving” (the pollsters’ summary words). Three-quarters said the economy was not so good or poor. Over half, 55 percent, report themselves to be “worse off” since Biden became president, 14 percent more than those saying they were “better off.”

People haven’t heard much about Biden’s economic policies, but only a quarter think they’ve helped. They’ve probably forgotten all the pandemic relief — stimmy checks, expanded unemployment, child allowances. Instead, now they complain overwhelmingly about price increases — 82 percent of them. Erik Gordon, a professor at Ross, told the Financial Times: “Every group — Democrats, Republicans and independents — list rising prices as by far the biggest economic threat . . . and the biggest source of financial stress.” Aside from inflation, other prominent complaints include “your income level,” rent, credit cards, and medical expenses.

The alleged decline in inequality is also not reflected in data compiled by the Real Time Inequality project out of the University of California at Berkeley. As the graph shows, the higher you are in the income distribution, the better you’ve done under Joe from Scranton. The top 0.1 percent has gained well over three times as much as the bottom half.

Critics and Defenders

Biden’s defenders say all these evaluations are wrong. As I asked in my piece on inflation for Jacobin last September, do these people ever go shopping for groceries?

These are the realities of living in the Biden economy. What’s his administration trying to do about them? The COVID-relief measures — the income supports, the student and mortgage debt moratoria — were immensely helpful to millions of people, but temporary. If made permanent, they could have been the cornerstone of a civilized welfare state. Yes, this would have been a difficult fight, but Biden could have made an issue of it. He didn’t.

What he has made an issue of, though not in a very arresting way, are those “smart investments in America.” The argument for spending for investment has not been advocated so strongly by a US president for decades, according to tax historian Joseph Thorndike. “Biden and his people were channeling Franklin Roosevelt in his purest form and unapologetically so,” he recently wrote in the Financial Times. “No one has made this argument with such freedom and such conviction since Roosevelt.”

That says as much about the last seven decades of Democratic presidents as it does about Biden. It’s hard to imagine anyone since FDR, except maybe Lyndon Johnson, who’s made such arguments.

Same with pro-union sentiments. Biden said in his Labor Day speech, “I’m proud to be the most pro-union president.” Contrast that with Robert Reich, freshly installed as Bill Clinton’s secretary of labor, who said in 1993 “The jury is still out on whether the traditional union is necessary for the new workplace.” Reich has since changed his tune, but that was his party’s view in those days. Tech and globalization were changing everything. Unions, by weakly trying to resist, were brakes on progress.

Obama wasn’t as fervent as Clinton’s crew, but never seemed very partial to organized labor. An economic crisis, rising popular disgust with the state of things, and the emergence of something like a left inside and outside the Democratic Party smashed that consensus.

And so, we got the three major investment bills: the Bipartisan Infrastructure Law (BIL, whose name conjures the elusive centrist dream of across-the-aisle partnership), the CHIPS Act, and the Inflation Reduction Act (IRA). The BIL is slated to invest $400 billion in infrastructure projects, about three-quarters of it in roads and bridges — many of which, as anyone who drives around this great land knows, are wrecks. But roads and bridges aren’t the conduits of the future, even if the law subsidizes electric car chargers. Ports, public transit, water projects, and the power grid also get some cash. According to a White House spreadsheet, $132 billion in funding has been announced so far — and just 4% of it is for public transit.

The CHIPS Act is meant to stimulate domestic electronics production. It’s doing some of that, but as I noted in an earlier piece on the law, its corporate subsidies are effectively a reimbursement for massive stock buyback programs by the big semiconductor firms over the last decade. Subsidies and tax breaks have spurred capital spending in the sector — though, as the graph below shows, the rest of manufacturing looks moribund. (Despite all the attention the sector gets, computers and electronics account for just 1.2 percent of GDP.)

That construction boomlet is at the mercy of corporate priorities. Chip demand is weakening, and over the summer, firms like Intel and Micron announced capital spending cuts despite their promises to boost investment. And though the government is picking up the tab for the investment spending, any profits will accrue to the companies and their shareholders. Something a pro-union president should be paying attention to — labor conditions at the Taiwan Semiconductor Manufacturing Company construction site in Arizona, a $40 billion project, the biggest announced so far — is hardly a worker’s dream. As the American Prospect’s Lee Harris found, the jobs are dangerous and largely nonunion, and embedded in an opaque web of subcontractors.

The IRA was a watered-down version of the Build Back Better bill, which was introduced in July 2021. Original schemes included ambitious spending on social programs (universal pre-K, child credits), clean energy, housing, education, health care, labor law reform, and high-speed rail, funded by higher taxes on corporations and rich people. Its original price tag was cut from $3.5 trillion to $2.2 trillion. But even the pared-down bill was too much for the Senate, particularly Joe Manchin, so the IRA was the compromise that got through.

The law aims to invest $891 billion, most of it on energy and climate, with some allocation to Obamacare subsidies. To raise revenue, the IRA features modest business tax hikes and $80 billion for “modernizing” the IRS, which is supposed to boost collections by much more than that $80 billion by cracking down on evaders, rather than formally increasing tax rates.

An early analysis of the IRA by the Rhodium Group, a consulting outfit, estimates that US greenhouse gas emissions will be 40 percent lower in 2030 than now, 10 percentage points less than in a non-IRA world. (An updated analysis from Rhodium and multiple other authors tweaked those figures, but left them substantially intact.) Ten percentage points is something, but “transformative” isn’t the first word that comes to mind.

The main mechanism of the reduction is making electricity generation cleaner and using more of it (especially by electric vehicles charged with the cleaner juice). Much of that decarbonization will come from tax credits (including for EVs), not direct public spending. A ledger kept by Rhodium and MIT’s Center for Energy and Environmental Policy Research shows that clean energy investment by the private sector, which was already rising briskly before the IRA, has been rising much more briskly since.

“A Business-First Approach”

This points to a problem with much of the Biden policy trio: private investment, not public investment, will be the principal lever. As a the White House put it in an IRA explainer, it’s an effort to “mobilize financing and leverage private capital.” That was describing one program, but it’s applicable to the entire assemblage. Incentives are supposed to trigger private investments that are many multiples of public spending — $3 trillion, on Goldman Sachs’s projections. As tech pundit David Kirkpatrick told Worth magazine, “This is a business-first approach to government climate action.”

Giddy celebrations of the package as a new New Deal overlook how firmly embedded Biden is in the ongoing preeminence of private capital. Ronald Reagan and his “magic of the marketplace” is still casting a long shadow. FDR was no socialist — quite the contrary — but his administration did show an interest in public investment that’s utterly lacking in Biden’s. (For evidence, check out some of the Living New Deal’s maps. We’re still using that infrastructure, constructed almost a century ago.) And, as the Right constantly laments, “In making the case [for higher taxes on the rich, FDR] unleashed moralistic rhetoric on fairness and fiscal citizenship that reshaped American taxation for decades to come.” Those decades, however, are long past.

Nor is Biden doing much to kill fossil capital, an urgent task. US domestic oil production since Biden took office is higher than it was during the Trump years (and more than twice as high as during the George W. Bush years, as you can see in the graph below). Rhodium projects that the IRA will have no impact on US oil production and promote only a modest decline in natural gas.

The approach seems to be to continue pumping to facilitate the energy transition, which is reminiscent of Ronald Reagan’s early 1980s “build down” approach to arms control — building more nuclear weapons now to pare them down at some unspecified later date.

Finally, although the Biden programs are pitched as measures to improve the lot of American workers, a central animating motivation is fighting a new Cold War with China, as the country becomes a tech power in its own right and not just a low-cost assembler of components designed elsewhere. Ruling elements, as we used to say on the old left, are not happy about having a country they see as an enemy, potential or actual, providing so many components for both consumer gadgets and weapons.

Always the “But”

Joe Biden hasn’t been Obama 2.0. His administration’s policies have prompted rumblings of a break with neoliberalism and attracted defenders with bona fide progressive credentials. Gone is the decades-long allergy to full employment or talk of industrial policy.

But, with Biden — to steal a line from Gore Vidal, who said it about America — there is always the “but.” Pro-union, but he busted a rail strike. Pro–public investment, but mostly stimulating private investment. Pro-climate but doing little to subdue oil and gas (though, yes, there is a Congress that loves oil and gas). Supposedly the biggest agenda in decades, but promoted with so little political skill or energy.

As Bloomberg News put it in August, “‘If you even gave a small summary of what is in the Biden legislative packages, all of those things are incredibly popular,’ Biden pollster John Anzalone said. ‘It’s the awareness level that’s really low.’” Or, as a Washington Post–University of Maryland poll found, most Americans (57 percent) oppose Biden’s climate policies but only a quarter or a third know anything about them. You can blame the media for that, in part — capital spending doesn’t bring in the clicks, and all these technical and financial details bore mainstream political journalists.

But it’s also Biden, who is dull and doesn’t always seem oriented in time and space. Trump had little positive to sell, but he never stopped selling it. As crass as that is, the strategy does pay political dividends. Biden has barely started selling. Lacking any visible economic message — a “vision” seems beyond his capabilities — bad feelings about inflation will continue to dominate whatever the long-term payoff of the Inflation Reduction Act.

If Biden wants to get reelected, he’s got to hope that people’s experience of inflation catches up with the official statistics — prices may be rising more slowly than they were, but they’re still rising rather than receding. And he’s got to convince people not merely that he has a long-term economic agenda, but that it might have some positive effect on their lives. Doing that would require evoking some common notion of a better future. But that would be very difficult for someone who mostly gives the impression of being tired and distracted.


Doug Henwood edits Left Business Observer and is the host of Behind the News. His latest book is My Turn.

Fanatical MAGA Republicans hold the country hostage over debt limit / by John Bachtell

U.S. Rep. Marjorie Taylor Greene, R-Ga., speaks about Twitter, April 28, 2022, on Capitol Hill in Washington. Once shunned as a political pariah for her extremist rhetoric, the Georgia lawmaker who spent her first term in Congress stripped of institutional power by Democrats is being celebrated by Republicans and welcomed into the GOP fold. | Jacquelyn Martin

On January 19, the U.S. government reached its debt limit. Without raising the debt ceiling, the government risks defaulting and shutting down functions and services, possibly triggering a domestic and global economic crisis.

Instead of raising the debt limit, which is nothing more than agreeing to pay bills already owed, the new GOP-MAGA fascist House majority is inching to create a political crisis by holding the country hostage. In exchange for raising the debt limit and reopening the government, they will demand a balanced federal budget in ten years, and draconian cuts to Medicare, Medicaid, Social Security, and repeal of the Affordable Care Act, something President Biden, and the Democrats will never agree to.

The fanatical GOP-MAGA House Majority’s first order of business was the passage of a phony populist bill, the “Family and Small Business Taxpayer Protection Act.” The hastily drawn legislation repeals funding for the Internal Revenue Service (IRS) adopted in the last Congress.

If this wasn’t loony enough, GOP-MAGA introduced another even more extreme bill – the Fair Tax Act, which would abolish the IRS, eliminate income, payroll, and estate and gift taxes and impose a 30% national sales tax on all goods and services, which the states would administer.

The GOP knows these bills will never become law. Senate Democrats will let them die, and President Biden vowed a veto if it ever reached his desk. “National sales tax, that’s a great idea,” Biden said sarcastically. “It would raise taxes on the middle class by taxing thousands of everyday items from groceries to gas while cutting taxes for the wealthiest Americans.”

The GOP-MAGA dysfunction and radical agenda have resulted in a 64% unfavorable rating (26% favorability) in the latest polls, matching polling following the January 6 insurrection.

Repealing IRS funding and eliminating income taxes is meant to provide a populist cover for the GOP and MAGA fascists, their billionaire backers, and allied movement’s quest to capture absolute governmental power and the presidency in 2024. The GOP and radical MAGA movement want to undemocratically and violently, if necessary, impose minority rule on the majority.

The MAGA movement and its billionaire backers envision a class, racial, and patriarchal hierarchy and theocratic order that turns back decades of progress on democratic rights and expansion of social benefit programs. Their goal is unfettered capitalism without restraints on profitmaking and wealth accumulation and eliminating social benefits, constitutional democracy, and democratic rights.

And the GOP and MAGA fascists aim to use the state’s power, including the courts and security apparatus, to guarantee their permanent rule through voter suppression, extreme gerrymandering, elimination of citizen-initiated referendums, suppression of organized labor and other democratic movements. The GOP-MAGA movement is imposing this autocratic model in states where they have entrenched power.

Obsession with gaining power

The obsession with gaining power, infighting, rivalry among MAGA radicals, political polarization, obstruction, chaos, and enshrining their permanent rule are hallmarks of fascism. People become alienated, and confidence in government is undermined – fertile grounds for the entrance of a “strong man” to impose order and “restore America to its glory days.”

The MAGA-GOP and their billionaire backers have long vilified the IRS and called for eliminating it. They demagogically claim to be the party of lower taxes for working people and small businesses. But inevitably, the GOP unabashedly cuts taxes on the very wealthy and corporations and then demagogically uses resulting deficits to cut social benefit programs.

The GOP began actively slashing corporate taxes under Reagan and IRS funding under Newt Gingrich and the GOP Congress in 1994. The words of Grover Norquist guide them: “My goal is to cut government in half in twenty-five years, to get it down to the size where we can drown it in the bathtub.”

Today, the GOP is blatantly lying about funding for the IRS in the Inflation Reduction Act (IRA). They claim, without basis, that it goes to hiring 87,000 IRS agents to invade the private lives of ordinary Americans. What’s worse than an IRS agent knocking on your front door while you’re eating breakfast?

In fact, the popular IRA, passed by the Democratic Congress and signed by President Biden in 2022, bolsters the severely underfunded IRS to clear a backlog of unprocessed returns, overhaul technology, and improve customer service, including services to working-class taxpayers needing help.

But the IRA also directs substantial funding to collect unpaid taxes by super-wealthy people and corporations. The non-partisan Congressional Budget Office (CBO) estimates the bill will generate $204 billion in revenues through 2031. Congress also passed a 15% minimum corporate tax as part of the Inflation Reduction Act.

The act is a step toward clawing back from the wreckage caused by Trump and the GOP Congress from the 2017 GOP tax cut to corporations, a massive boondoggle for the rich. The CBO estimated in 2018 the legislation would increase deficits by about $1.9 trillion over 11 years. Repealing IRS funding will add another $114 billion to the deficit over ten years.

The rich get away with not paying taxes because the IRS enforcement division was deliberately defunded and disabled by past GOP Congresses and presidents. Between 2010 and 2018, funding fell by 24%, leading to the loss of 17,000 employees.

“Funding cuts have cost the IRS much of its most experienced staff: the number of Revenue Agents fell by 35 percent between 2010 and 2018, to the lowest number since 1954,” testified Chye-Ching Huang, Director of the Economic Policy Institute, before Congress.

In 2021, the IRS reported that the federal government was losing $1 trillion in unpaid taxes annually, mainly by the wealthy and corporations. The top 5% of rich people avoided paying $307 billion in taxes, and the top 1% alone avoided paying $163 billion.

Voters have rejected the GOP in three straight elections, and Democrats have won the majority vote in seven of the last eight presidential elections. The GOP-MAGA extreme right and fascists know their agenda is unpopular with most American voters and can only achieve it through undemocratic means. Only a mobilized anti-MAGA majority stands in the way of this nightmare scenario. There are signs that the majority is beginning to turn back the right-wing assault, but more on that in coming Peoples World articles.


John Bachtell is president of Long View Publishing Co., the publisher of People’s World. He served as national chair of the CPUSA from 2014 to 2019. He is active in electoral, labor, environmental, and social justice struggles. He grew up in Ohio, Pittsburgh, and Albuquerque and attended Antioch College. He currently lives in Chicago where he is an avid swimmer, cyclist, runner, and dabbler in guitar and occasional singer in a community chorus.

People’s World, January 20, 2023, https://www.peoplesworld.org/